Cancer clinical trials in the region Provence-Alpes-Côte d'Azur
130 currently recruiting clinical trials
If you are a doctor and would like find matching clinical trials for you patients, create an account or log in
If you are a patient and would like to know if you may participate in a clinical trial, please consult your doctor so that he can send your file to a matching trial
Phase 3
Lung cancer
#NCT05668988
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
Metastatic
EGFR
Systemic Treatment-Naive
Centre Hospitalier Universitaire de Nantes (Nantes), Hôpital d'instruction des Armées Bégin (Saint-Mandé), Centre Hospitalier Universitaire Angers (Angers ), Centre Hospitalier Intercommunal Créteil (Créteil Cedex), Centre Hospitalier Universitaire de Grenoble (La Tronche) (and 7 more...)
Debiopharm International SA
Phase 3
Lung cancer
#NCT05607550
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
Metastatic
EGFR
Systemic Treatment-Naive
Immunotherapy
Targeted therapy
Car-T
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
Centre François Baclesse (Caen ), Centre Léon Bérard (Lyon), Hôpital de la Croix Rousse - Hospices Civils de Lyon (Lyon), Hôpital Nord de Marseille (Marseille Cedex 20), Gustave Roussy (Villejuif) (and 1 more...)
ArriVent BioPharma, Inc
Phase 3
Lung cancer
#NCT05555732
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
Metastatic
Systemic Treatment-Naive
PDL1 Negative (< 1%)
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
EGFR
BRAF
MET
ALK
RET
ROS-1
NTRK-1/2/3
Other mutation
Immunotherapy
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
Immunotherapy
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
Centre Hospitalier Universitaire de Nantes (Nantes), Centre Hospitalier Universitaire de Montpellier - Site de Saint Eloi (Montpellier), Centre Hospitalier Universitaire de Poitiers - Site de la Milétrie (Poitiers), Centre Léon Bérard (Lyon), Hôpital Foch (Suresnes) (and 5 more...)
Daiichi Sankyo
Phase 3
Lung cancer
#NCT06151574
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
Metastatic
HER2
Systemic Treatment-Naive
CHU de Rennes - Hôpital Pontchaillou (Rennes), Hôpital Tenon AP-HP (Paris ), Institut Curie - Paris (Paris), Centre Hospitalier Universitaire de Strasbourg - Nouvel Hopital Civil (Strasbourg), Centre Léon Bérard (Lyon) (and 1 more...)
Boehringer Ingelheim
Phase 3
Breast cancer
#NCT05382286
HER2 Negative
HR Negative
Locally Advanced
Metastatic
Systemic Treatment-Naive
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
Immunotherapy
Immunotherapy
Bispecific T-cell engager antibodies
Institut Sainte Catherine (Avignon), Centre Hospitalier Universitaire de Besançon (Besançon), Polyclinique Bordeaux Nord Aquitaine (Bordeaux), Centre François Baclesse (Caen ), Centre Jean Perrin (Clermont Ferrand ) (and 9 more...)
Gilead Sciences
Phase 3
Lymphoma
#NCT05371093
B cell lymphoma
Follicular lymphoma
None
Chemotherapy
Targeted therapy
1
2
3 or more
Systemic Treatment-Naive
Car-T
Centre Henri Becquerel (Rouen ), Centre Hospitalier Universitaire de Montpellier - Site de Saint Eloi (Montpellier), Hôpital Pitié Salpêtrière - AP-HP (Paris), Hôpital Henri-Mondor AP-HP (Créteil), Institut Paoli-Calmettes (Marseille) (and 6 more...)
Kite, A Gilead Company
Phase 3
Lung cancer
#NCT05215340
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
Systemic Treatment-Naive
PDL1 Positive (>= 50%)
EGFR
BRAF
MET
ALK
RET
ROS-1
NTRK-1/2/3
Immunotherapy
Targeted therapy
Antibody Drug Conjugates (ADC)
Immunotherapy
Chemotherapy
Targeted therapy
Antibody Drug Conjugates (ADC)
Institut Bergonié (Bordeaux), Centre Hospitalier Universitaire de Lille (Lille), Centre Hospitalier Universitaire de Montpellier - Site Arnaud de Villeneuve (Montpellier), Hôpital Tenon AP-HP (Paris ), Hôpital Foch (Suresnes) (and 6 more...)
Daiichi Sankyo
Phase 3
Lung cancer
#NCT05211895
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Chemotherapy
Radiotherapy
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
EGFR
ALK
Institut de Cancérologie de l'Ouest - Site d'Angers (Angers ), Centre Hospitalier François Mitterrand de Pau (Pau), Centre Hospitalier de Cornouaille (Quimper), Institut de Cancérologie Radiothérapie Brétillien / CHP Saint Grégoire - Vivalto Santé (Saint-Grégoire), Centre Hospitalier de Saint Quentin (Saint-Quentin) (and 7 more...)
AstraZeneca
Phase 3
Breast cancer
#NCT05774951
HER2 Negative
HR Positive
Localized
Surgery
Hormone therapy
Centre Hospitalier d'Avignon (Avignon), Hôpital Lyon Sud - Hospices Civils de Lyon (Pierre-Bénite), Centre Hospitalier d'Argenteuil (Argenteuil), Centre Hospitalier Universitaire de Bordeaux (Bordeaux), Groupe Hospitalier Saint André (Bordeaux) (and 20 more...)
AstraZeneca
Phase 3
Prostate cancer
#NCT04916613
Metastatic Hormone-sensitive
Systemic Treatment-Naive
Institut Sainte Catherine (Avignon), Centre Hospitalier de la Côte Basque (Bayonne), Centre Hospitalier Universitaire de Besançon (Besançon), Institut Bergonié (Bordeaux), CHP Brest - Pasteur Vivalto Santé (Brest) (and 35 more...)
UNICANCER